BACKGROUND: Both cognitive tests and MRI-based measures have been suggested as outcomes in trials assessing disease-modifying therapies in Alzheimer's disease (AD). OBJECTIVE: To compare changes in longitudinal MRI measures with changes in performance on cognitive tests routinely used in AD clinical trials. METHOD: Fifty-two subjects from the placebo-arm of a clinical trial in mild-to-moderate AD had volumetricT(1)-weighted scans and cognitive tests including the Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale, Disability Assessment for Dementia, AD Cooperative Study-Clinical Global Impression of Change and Clinical Dementia Rating at baseline and one-year later. Rates of brain atrophy and ventricular enlargement were measured using the boundary shift integral. Hippocampal (Hc) atrophy was calculated from manual volume measurements. The relationships between MRI and cognitive measures were investigated. RESULTS:Rates of brain atrophy and/or ventricular enlargement were correlated with declining performance on cognitive scales. The strongest association was between brain atrophy rate and MMSE decline (r = 0.59, p < 0.0001). Hc atrophy rate was not significantly correlated with any of the cognitive scales. CONCLUSION: The lack of correlation between Hc atrophy and cognitive scales may reflect a combination of: the extensive functional damage to the Hc by the time AD is clinically established, the greater influence of ongoing cortical degeneration, and errors in Hc outlining. The strong correlations between brain atrophy and ventricular enlargement, and cognitive scales probably reflect the correspondence between these measures of overall cerebral loss and global cognitive measures in the moderate stages of AD.
RCT Entities:
BACKGROUND: Both cognitive tests and MRI-based measures have been suggested as outcomes in trials assessing disease-modifying therapies in Alzheimer's disease (AD). OBJECTIVE: To compare changes in longitudinal MRI measures with changes in performance on cognitive tests routinely used in AD clinical trials. METHOD: Fifty-two subjects from the placebo-arm of a clinical trial in mild-to-moderate AD had volumetric T(1)-weighted scans and cognitive tests including the Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale, Disability Assessment for Dementia, AD Cooperative Study-Clinical Global Impression of Change and Clinical Dementia Rating at baseline and one-year later. Rates of brain atrophy and ventricular enlargement were measured using the boundary shift integral. Hippocampal (Hc) atrophy was calculated from manual volume measurements. The relationships between MRI and cognitive measures were investigated. RESULTS: Rates of brain atrophy and/or ventricular enlargement were correlated with declining performance on cognitive scales. The strongest association was between brain atrophy rate and MMSE decline (r = 0.59, p < 0.0001). Hc atrophy rate was not significantly correlated with any of the cognitive scales. CONCLUSION: The lack of correlation between Hc atrophy and cognitive scales may reflect a combination of: the extensive functional damage to the Hc by the time AD is clinically established, the greater influence of ongoing cortical degeneration, and errors in Hc outlining. The strong correlations between brain atrophy and ventricular enlargement, and cognitive scales probably reflect the correspondence between these measures of overall cerebral loss and global cognitive measures in the moderate stages of AD.
Authors: C R Jack; M Slomkowski; S Gracon; T M Hoover; J P Felmlee; K Stewart; Y Xu; M Shiung; P C O'Brien; R Cha; D Knopman; R C Petersen Journal: Neurology Date: 2003-01-28 Impact factor: 9.910
Authors: J-M Orgogozo; S Gilman; J-F Dartigues; B Laurent; M Puel; L C Kirby; P Jouanny; B Dubois; L Eisner; S Flitman; B F Michel; M Boada; A Frank; C Hock Journal: Neurology Date: 2003-07-08 Impact factor: 9.910
Authors: H Randall Griffith; Christopher C Stewart; Luke E Stoeckel; Ozioma C Okonkwo; Jan A den Hollander; Roy C Martin; Katherine Belue; Jacquelynn N Copeland; Lindy E Harrell; John C Brockington; David G Clark; Daniel C Marson Journal: J Am Geriatr Soc Date: 2010-01-26 Impact factor: 5.562
Authors: Lenore J Launer; Michael E Miller; Jeff D Williamson; Ron M Lazar; Hertzel C Gerstein; Anne M Murray; Mark Sullivan; Karen R Horowitz; Jingzhong Ding; Santica Marcovina; Laura C Lovato; James Lovato; Karen L Margolis; Patrick O'Connor; Edward W Lipkin; Joy Hirsch; Laura Coker; Joseph Maldjian; Jeffrey L Sunshine; Charles Truwit; Christos Davatzikos; R Nick Bryan Journal: Lancet Neurol Date: 2011-09-28 Impact factor: 44.182
Authors: Shantell C Nolen; Brian Lee; Shruti Shantharam; Hon J Yu; Lydia Su; John Billimek; Daniela A Bota Journal: J Neurooncol Date: 2016-07-08 Impact factor: 4.130
Authors: Sarah K Madsen; Boris A Gutman; Shantanu H Joshi; Arthur W Toga; Clifford R Jack; Michael W Weiner; Paul M Thompson Journal: Multimodal Brain Image Anal (2013) Date: 2013
Authors: Xue Hua; Alex D Leow; Neelroop Parikshak; Suh Lee; Ming-Chang Chiang; Arthur W Toga; Clifford R Jack; Michael W Weiner; Paul M Thompson Journal: Neuroimage Date: 2008-07-22 Impact factor: 6.556
Authors: Sean M Nestor; Raul Rupsingh; Michael Borrie; Matthew Smith; Vittorio Accomazzi; Jennie L Wells; Jennifer Fogarty; Robert Bartha Journal: Brain Date: 2008-07-11 Impact factor: 13.501